Cantor Fitzgerald reiterates Neutral on Tvardi Therapeutics stock

try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Trump considering pulling U.S. out of NATO alliance - The Telegraph Oil oscillates around $100 as Trump says Iran war could end soon Futures gain, oil tumbles, amid hopes for end to Iran war - what’s moving markets Asia stocks surge as Trump touts end to Iran war; S.Korea outperforms with 8% jump (South Africa Philippines Nigeria) Cantor Fitzgerald reiterates Neutral on Tvardi Therapeutics stock By Analyst Ratings Published 04/01/2026, 07:54 AM Cantor Fitzgerald reiterates Neutral on Tvardi Therapeutics stock 0 TVRD -0.63% Investing.com - Cantor Fitzgerald reiterated a Neutral rating on Tvardi Therapeutics Inc (NASDAQ:TVRD) following the company’s fourth-quarter 2025 earnings report. The stock, currently trading at $3.18 with a market cap of $29.27 million, has declined 82.57% over the past year and sits near its 52-week low of $3.05. The firm’s focus remains on Tvardi’s next-generation pro-drug asset, TTI-109, which is expected to have a better therapeutic index compared to the parent drug, TTI-101. TTI-101 did not succeed in the recently completed Phase 2 REVERT IPF study, in part because many patients were on an additional poorly tolerated IPF drug called nintedanib. Cantor Fitzgerald views TTI-109 as a potential lever to unlock the potential of STAT3 biology, or at least a higher probability test of the hypothesis. Tvardi expects to report data from a healthy volunteers study of TTI-109 in the second quarter of 2026, which should provide some indication of the drug’s tolerability profile. Assuming TTI-109 tolerability appears acceptable, the firm anticipates the company will need to finance further development, which is expected to be outside IPF. According to InvestingPro data, Tvardi holds more cash than debt on its balance sheet with a current ratio of 3.48, providing some financial flexibility. The platform’s Fair Value analysis suggests the stock may be undervalued at current levels. Possibilities in...